ESSA Pharma (ESSA Pharma) ROE % Adjusted to Book Value : -8.05% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma ROE % Adjusted to Book Value?

ESSA Pharma's ROE % for the quarter that ended in Dec. 2023 was -16.66%. ESSA Pharma's PB Ratio for the quarter that ended in Dec. 2023 was 2.07. ESSA Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -8.05%.

ESSA Pharma ROE % Adjusted to Book Value Historical Data

The historical data trend for ESSA Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma ROE % Adjusted to Book Value Chart

ESSA Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-30.69

-13.11

-14.88

-40.50

-18.09

ESSA Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-23.75	-21.12	-24.11	-15.77	-8.05

Competitive Comparison of ESSA Pharma's ROE % Adjusted to Book Value

For the Biotechnology subindustry, ESSA Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ESSA Pharma's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's ROE % Adjusted to Book Value falls into.

ESSA Pharma ROE % Adjusted to Book Value Calculation

ESSA Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-17.00%	/	0.94
	=	-18.09%

ESSA Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-16.66%	/	2.07
	=	-8.05%

ESSA Pharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

ESSA Pharma (ESSA Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5

Website

https://www.essapharma.com

ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.

Executives

Peter Virsik	officer: Chief Operating Officer	131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson	director, officer: Chief Executive Officer	C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood	officer: Chief Financial Officer	3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Biotech Growth N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Philip W. Kantoff	director	3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104